中文 ENGLISH

About AVATARGET

Company Profile

-- All-inclusive organ-on-a-chip solutions provider

Avatarget Co., Ltd. (Avatarget) is dedicated to R&D and production of organs-on-chips, smart equipments, biological reagents, and other products and services, aiming to build a whole-industry-chain ecosystem for organs-on-chips. It also desires to innovate and break through the limitations of traditional animal models and 2D cell models to address species differences and achieve 3D dynamic cultivation of in vitro models. Also, it seeks to create a highly simulated human body micro-environment and enhance the accuracy of experimental data in order to provide precise and effective products and solutions for users in fields such as tumor precision medicine, disease modeling, drug screening, drug evaluation, cosmetics evaluation, regenerative medicine research and space medicine research.

Big

R&D Lab

Products & Applications

Percentage of PhDs

Percentage of R&D personnel

Vision

Become a leader in the field of OoCs

Mission

Care for life with "core"

Values

Truth Innovation Endeavor Cooperation mutual benefits

2025年

2025.11，Avatarget's skin chip technology was selected as an advanced technological innovation achievement in the light industry during the 14th Five-Year Plan period, making it the only project selected in the fragrance and cosmetics sector.

2025年

2025.09 Avatarget skin chip was selected as one of the top ten technological advancements in China's cosmetics industry in 2025.

2025年

2025.07 Professors Gu Zhongze and Chen Zaozao have been appointed to important positions in the International Union of Microphysiological Systems.

2025年

2025.06 Avatarget empowers the official release of the world's first DILI large-scale model.

2025年

2025.05 Avatarget's human organ-on-a-chip project won the 2025 VBEF "Best Biotechnology Innovation Product" award.

2025年

2025.02 Avatarget has been selected for the 2024 Suzhou "Unicorn" Cultivation Enterprise List.

2025年

2025.01 Avatarget was selected as an outstanding innovative case in Arterial Network's "Innovative Drugs and Supply Chain White Paper".

2024年

2024.12 Avatarget was selected as a "Jiangsu Provincial Postdoctoral Innovation Practice Base" and was selected as one of the "Seven Major Advances in Space Human Research".

2024年

2024.11 Avatarget Participates in Release of Expert Consensus on Liver Organ-Chips for Drug Safety Prediction; "Multimodal Precision Measurement Technology and Application of Human Organ-Chips" Wins Second Prize in Golden Bridge Award Projects

2024年

2024.10 The first organ-on-a-chip technology standard in China, "General Technical Requirements for Skin Chips," which I helped draft, has been officially released.

2024年

2024.09 Avatarget Biotech Selected for Jiangsu's List of Potential Unicorn Companies

2024年

2024.03 The project on the development of human organ-on-a-chip and multimodal precision measurement methods was selected as one of the "Top 10 Advances in Life Sciences in China in 2023".

2024年

2024.02 Awarded Suzhou High-tech Zone's 2023 High-Growth Innovative Enterprise

2023年

2023.12 Recognized as a National High-tech Enterprise; completed a Pre-A+ round of financing led by Tongfang Investment.

2023年

2023.11 Selected for the 2023 Jiangsu Potential Unicorn Companies List; Huawei's Pangu + Organ Chip: The World's First Large-Scale Medical Model for Human Organ Chips Released

2023年

2023.08 The first domestic experiment of cultivating organ-on-a-chip in space was successfully completed on the Chinese space station, and it is also the world's first study of artificial blood vessel tissue-on-a-chip in space.

2023年

2023.05 In collaboration with Hengrui, China's first new drug using organ-on-a-chip data has been approved for clinical trials.

2022年

2022.10 Organ-on-a-chip project selected for the Ten-Year Achievement Exhibition of Science and Technology Innovation by Overseas Chinese

2022年

2022.06 Completed Pre-A round financing led by Rehabilitation Capital

2022年

2022.03 Winner of the highest award at the first National Disruptive Technology Innovation Competition

China's first

OoC to enter the space station for scientific experiments

China's first

OoC for IND application

China's first

Technical standard for OoCs

Patent Portfolio

Through industry-university-research cooperation and independent R&D, AVATARGET has applied for nearly 100 patents, of which 50% are invention patents, covering core products such as OoCs, bio-models & materials, instruments and software. We have completed the Pre-A round of financing of nearly RMB100 million led by Fosun Health Capital.

Our skin-on-a-chip technology, as the China’s OoC model standard, has been approved by the Standardization Administration of the People’s Republic of China (SAC).

Value Recognition

Since its establishment, AVATARGET has achieved a number of awards and honors, including “Potential Unicorn Company in Jiangsu”, “Winning Prize in the Finals of the 1st National Disruptive Technology Innovation Competition”, “First Prize of the 9th Overseas Chinese Contribution Award”, “Enterprise in Suzhou New District Leading Entrepreneurial Talent Program”, “Second Prize of the Jiangsu Information Consumption Competition”, “Enterprise Leading Talents of Entrepreneurship in Gusu District”, and “China Patent Excellence Award”. In addition, we have made achievements such as “China’s first OoC to enter the space station for scientific experiments”, “China’s first OoC for IND application”, and “the technical standard for OoCs approved in China”, and completed the Pre-A round of financing of nearly RMB100 million led by Fosun Health Capital.

Ava’target (Alpha Target) Strive for Perfection

Our human OoC project has crossed the last kilometer from the R&D to application.

Avatar'get (Avatar Get) Substitution Test

We are building a full industry chain ecosystem of OoC technologies to gain insights into the mysteries of life sciences, contribute to medical technology advancement, and meet the individual needs of patients.

2024-03

2024-01

2023-08

2023-05

2022-12

2022-08

2022-06

2021-01

2020-02

2019-01

2018-01

2013-01

2011-01

2010-01

The project of human organ-on-chip and multimodal precision measurement method construction selected as one of China’s Top 10 Science Advances in 2023

The Center of NMPA issued the Technical Guidelines on Non-clinical Studies of Human Stem Cell-based Products, which explicitly includes new technologies such as organoid into the evaluation models for non-clinical studies of human stem cell-based

The first space OoC culture experiment in Chinese’s space station, also the first international Taikonaut-Blood-Vessels-on-a-Chip study

HRS-1893 tablets were approved for clinical trials, which is the first breakthrough of organoid data outside the realm of CGT drugs

U.S. President Biden signed into law the FDA Modernization Act 2.0, eliminating federal mandatory requirement for animal testing for new and generic drugs

General Technical Requirement of Skin-on-a-chip, China’s first draft technical standard for OoCs, was published

For the first time, the FDA had approved the clinical trial of an investigational therapy based solely on preclinical efficacy data obtained in human OoC studies

The U.S. House of Representatives passed the Food and Drug Amendments of 2022, which includes OoCs and Microphysiological Systems (MPSs) as independent systems for evaluating drugs in non-clinical trials

Organoid research has been approved as a key special project of the National Key R&D Program in China’s 14th Five-Year Plan

The Center of NMPA published the Technical Guidelines on Nonclinical Studies of Genetically Modified Cell Therapy Products, allowing for the use of cell- and tissue-based models to provide useful supplemental information for efficacy and safety evaluation

Southeast University in China developed a bronchial-lung-on-chip that could be used for the evaluation of COVID-19 infections and treatments, and applied it at the Jiangsu Provincial Center for Disease Control and Prevention

FDA used lung-on-chips to evaluate the safety of COVID-19 vaccines and their protective immunity against SARS-CoV-2

The U.S. Environmental Protection Agency (EPA) has announced that it will stop funding all mammal testing by 2035

California has banned cosmetic testing on animals

The EU has imposed a ban from testing finished cosmetic products and cosmetic ingredients on animals and from marketing finished cosmetic products and ingredients which were tested on animals

The U.S. government was the first to announce the launch of a human body-on-a-chip program, aiming to develop human body-on-a-chips for new drug development and toxicity prediction

Harvard University successfully developed the human lung-on-a-chip

Partners

Walk with you, side by side with success, we are here waiting for you to create the future together!

北京协和医院

中源生物

香港大学

301解放军总医院

东南大学

鼓楼医院

恒瑞

华中科技大学

集萃药康

江苏省疾病预防控制中心

江苏省人民医院

江苏省肿瘤医院

凯基生物

南京大学

南京正大天晴

赛赋医药

苏大附一医院

泰格医药

先声药业

昭衍

Honor

第一届江苏省信息消费大赛总决赛产品创新二等奖
中国创新创业大赛江苏赛区优秀企业
中国第一个进入空间站并实施科学实验的器官芯片
中国第一个器官芯片技术标准
中国第一个用于申请新药IND的器官芯片

Service Hotline(front desk)

+86 025-58858435

WeChat

Zhihu

Bilibili

Business License

We use optional cookies to improve your experience on our website, including through social media connections, and to personalize ads based on your online activity. If you refuse optional cookies, we will only use cookies that are necessary to provide you with the services.Privacy Statement